ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,021.63
0.57%
US Tech 100
20,355.20
0.45%
다우존스 지수
44,860.31
0.28%
Bitcoin
92,809.85
0.91%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Anavex Life Sciences Corporation (AVXL)

  7. Anavex Life Sciences Corporation (AVXL) 뉴스

Anavex Life Sciences Corporation

Anavex Life Sciences Corporation (AVXL)

NASDAQ
9.035
-0.095
(-1.04%)
마감 27 11월 6:00AM
15분 지연
9.0516
0.0166
(0.18%)
시간외 거래: 8:40AM
15분 지연

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

AVXL 뉴스

공식 뉴스 전용

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
07 8월 2024
AVXL (-1.04%)

Form 8-K - Current report
Edgar (US Regulatory)
31 7월 2024
AVXL (-1.04%)

Form S-3 - Registration statement under Securities Act of 1933
Edgar (US Regulatory)
30 7월 2024
AVXL (-1.04%)

AVXL Discussion

게시물 보기
mauismart mauismart 29 분 전
Great I pitched everything I had and even tried to sell when they were all gone. I knew they had to protect their short pile.
👍️0
k9uwa k9uwa 37 분 전
I pitched stock in the premarket. DITTO Mauismart netted $1.18 when I bought my shares back this afternoon. Didn't sell and rebuy a large percentage. But some of my shares.
John k9uwa
👍️0
mauismart mauismart 52 분 전
I pitched stock in the premarket trading session. I sold at 1035 1030 1000 and 9.97. I then bought back later in the day. I learned this along time ago. I did buy call options. They can't keep us down with these short selling programs forever.
👍️ 1
BIOChecker4 BIOChecker4 1 시간 전
OK, George. From now on we’ll believe every word you say.

Not.
👺 1 ❌️ 1
couldbebetter couldbebetter 1 시간 전
I thought Dr. M always stated he would partner for AD.
I wonder if having the right partner could make a difference
in seeking EMA approval. The better the reputation of AVXL's
partner, the greater the confidence in the drug(s). Having a
partner early on could help AVXL deal with the myriad of nations
that they would be seeking reimbursements from. Having the
right partner could make the process go smoother and faster.
Of course having a Eurocentric BP as a partner not only for
AD but other drugs as well makes good sense. The sooner
the better so plans could be in place and ready to go once
approval is granted!
👍️ 2 👎️ 1 👺 1
Steady_T Steady_T 2 시간 전
George, Congratulations. That's one in a row.
👎️ 1 👺 1
rx7171 rx7171 2 시간 전
So is AbbVie looking for a partner with a valid AD treatment on the threshold of getting to the market?
👍️ 3
Hosai Hosai 2 시간 전
Wonder to what degree Ozempic (Semaglutide) could eventually muscle in a little on Blarcamesine? Their P3 data on early AD I believe would be due in late 2025. They would likely therefore be a couple of years behind blarca if blarca approved late 2025 at-least in the EMA. The study is based on previous data on ppl with diabetes however the phase 3 is on general early AD population not just overweight or with diabetes - https://www.neurology.org/doi/10.1212/WNL.0000000000205079

I understand it has some bad side effects however that many may not want to face...it may also not work as-well in people who are not overweight, but then I also wonder to what degree blarca might also work better in less healthy people.
👍️0
Steady_T Steady_T 2 시간 전
Hopefully OLE data and a more in depth look at all the data. AND, more importantly, the data has been peer reviewed and is not just what the company says it is.
That gives the results MUCH MORE credibility.
👍️ 3
boi568 boi568 2 시간 전
I was in NYC with my wife for a few days a couple of weeks ago and it was delightful. I can only imagine what I was missing since it was so tragically ruined.
👍️ 1
williamssc williamssc 2 시간 전
Although not reported, I'm assuming the company requested accelerated approval.
👍️0
Hoskuld Hoskuld 2 시간 전
100% Mycroft. You were ahead of the curve. I was interested when they published what it said were the first 50 patients' data from their OL trial (it was 50 cherry-picked data sets but I didn't know that at the time.) But when the 2nd set came out and the results were very different then I was skeptical. And when their 3rd data set came out and it was pretty terrible then of course I knew it was a bust (and probably a fraud.) That was 3 years after you already called it - but 2 years before they actually failed. Shrkeli opined 3 days ago - way behind us.
👍️ 2
Hoskuld Hoskuld 2 시간 전
I think that is the date of the next meeting Sab?
👍️0
Hoskuld Hoskuld 2 시간 전
BakedLangostino, am catching up with messages. No, I don't "act like it's just wave your hands and qualified trial participants will appear en masse" - that is your attempt to minimize responsibility for not doing the right thing. The company itself said (in June) that this is what they should have done - and they are right.
👍️0
Hoskuld Hoskuld 2 시간 전
I mean...who decides on that change and how is that change made and what are the consequences other than a shorter review?
👍️0
williamssc williamssc 2 시간 전
Unmet need and a major public interest. Seems a good bet.
👍️ 1
Hoskuld Hoskuld 2 시간 전
UK, TGA...maybe Canada...probably not Japan because they require Japan-specific P3...
👍️ 1
Hoskuld Hoskuld 2 시간 전
What would cause this to happen William?
👍️0
Hoskuld Hoskuld 2 시간 전
I think that if the 3-71 data next Summer is very strong and the upcoming paper dispels some of the uncertainty that still lingers over the 2-73 P3 data and analysis and the OLE data is strong then a partner on good terms will not be hard to find. I expect this to happen next Summer/Fall but not before.
👍 2
williamssc williamssc 3 시간 전
Anavex receiving accelerated approval shouldn't be far behind their application. This could be a huge move for us.
👍️ 7 😃 1
tredenwater2 tredenwater2 3 시간 전
“ As soon as the MAA is officially accepted by the EMA, does Missling and team put on a full court press on to find a global partner?”

Pazzo I dont think the Anavex team can afford to wait. Nothing is moving the needle MC wise. With that being said, approval doesnt even guarantee the price will increase to anywhere near proper valuations. The crazy MC increases witnessed in companies in the past are imo either shorts getting trapped by a surprise announcement or large companies/brokers unloading a shitton of stock on funds they control, at least that is my impression of the (4), 20 billion dollar increased in biogens MC at the drop of news. Theres no other reason it could go up other than one hand buying from the other in an artificial manner through HFT trading…or what I refer to as “kissing cousins”.

Partnership announcement imo will come as we near approval for AD. Perhaps the ink will dry after the first (and maybe only) clock stop. The “deal” will include Parkinsons (upon a successfully ran, ready to ho, ph 3) and Alzheimers with one maybe two partners.

Will it be Merck and Takeda who are in our 3-71 consortium for Schizophrenia? This would be an easy way to currently tie them up with NDA’s and would satisfy Europe and Asia. I still believe that is what Dr. Missling did with Biogen to prevent them from getting to big for their britches. They still tried to “lift their leg” on us every CTAD or AAIC with their “drain cleaner” presentations but Dr. Missling kicked them to the curb, successfully, and marched on protecting what we have IP wise.

I honestly still cant wait to shake the mans hand. It just might not be at a ASM like I have envisioned unless our new admin can turn NY around. Ive taken visiting that state off my bucket list after the Dipcraps have ruined it.

One first down at a time. Sometimes its a game of inches. We just need to avoid any penalties right now which I feel confident he will.

Cheers

Tred
👍️ 13 😃 2
Talon38 Talon38 3 시간 전
quick finger
👍️0
Talon38 Talon38 3 시간 전
Another of our competitors down!

https://www.biospace.com/drug-development/alectors-abbvie-partnered-alzheimers-program-fails-phase-ii-triggering-a-17-layoff?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsenc=p2ANqtz--a5_0LE7GEXsD_Ytq_kovSGXKra4RLBIS2wV-RQ6zxmETw6f_owOSf-Fwy9Cq1RfGBHaSYDMhYLPL1B2WuwKrHbkNDUQ&_hsmi=335754218&utm_content=335754218&utm_source=hs_email
👍️ 3
frrol frrol 3 시간 전
The company reiterates its "worldwide" plans in the PR, but leaves timing for next application unclear (after MAA acceptance, after CHMP opinion...) I suspect we'll get clarity at the FYE CC.
👍️ 1
crescentmotor crescentmotor 3 시간 전
There could be other cayalysts such as PDD trial initiation or if they apply to other regulators such as FDA or as a smaller impact to UK, Canada, Aus/NZ or Japan.

Yes. I'm not really expecting any near term progress with the FDA. Probably the last thing AVXL wants in the near term is to meet with the FDA and possibly then have to disclose that the FDA has formally told them it is going to require a larger Phase III trial before it will consider regulatory approval. Something like that might have some negative spillover effect on the European review. Just thinking out loud about the possible scenarios moving forward--it's obviously all question marks at this juncture.
👍️ 2
frrol frrol 3 시간 전
The papers do get picked up by some bloggers and pop-science sites that scan the journals, not so much by general news media unless it's pretty big (like approvals). But you never know.
👍️ 1
crescentmotor crescentmotor 3 시간 전
As soon as the MAA is officially accepted by the EMA, does Missling and team put on a full court press on to find a global partner?

Good question. I wonder how much of the marketing/commercialization plan will be required to be laid out as part of the European regulatory review. There is no question that a partner will be needed for a commercialization phase. I suspect we will see a partner brought on board before the end of 2025 unless there are hiccups with the MAA review.
👍 2
Hosai Hosai 3 시간 전
There could be other cayalysts such as PDD trial initiation or if they apply to other regulators such as FDA or as a smaller impact to UK, Canada, Aus/NZ or Japan.
👍️0
georgejjl georgejjl 3 시간 전
I was correct again!!!

GOD bless,
👍️ 1
crescentmotor crescentmotor 3 시간 전
I'm bullish long term, Steve, but watching how AVXL is trading these days, It just looks like price is getting tossed up and down like a rag doll.

After the MAA is hopefully accepted, I think investors are perhaps in for a long, mostly uneventful, wait for many months (could easily be a year). I don't anticipate it will be a particularly exciting time to trade the stock. I suppose AVXL might start another trial in the interim, some schizophrenia results will be available around mid year, and a partnership for AD is not a longshot now that AVXL's feet are now planted firmly on a EU regulatory path. Anyway, after the SAVA fiasco, I will probably step back somewhat from watchin the market 24/7 and take a recovery break while AVXL's MAA cooks.
👍️ 1
frrol frrol 3 시간 전
You didn't. Either you don't understand or you're careless, neither's an excuse. This will help:
https://moxreports.com/kbio-infinity-squeeze/

Stop misleading yourself and others.
👍️ 2
Hosai Hosai 3 시간 전
Just to remind of this conference with Dr Missling in early Sept, he says at 13:30 - "We are actively now engaging with KOL's, physicians, with Alzheimers communities, to educate them about our drug and when the paper comes out this will be accelerating even further".

I'm wondering if we could see more mainstream media coverage following the paper release?

I also like at 16:55 where he talks about enhancing authophagy and how it's "really nicely demonstated in the paper, with Blarcamesine specifically, and it seems to be the key mechanism of Alzheimers disease and other pathologies as-well."

https://journey.ct.events/view/0adae96a-6102-40ae-90d4-ef4336266886
👍️ 4
123tom 123tom 4 시간 전
Good job, bas... I agree... and now time to look at the charts and find the pullback targets. Such a fun gambling game, isn't it.
What would Range patterns look like.
7.25 to 10.25 and back again... maybe the larger wave 5.00 to 10.00 and back to 5 ??
I'm looking at 7.50 target zone for now, but that might be just the high side of bargains.
Some targets around 6.80🤔 ? ... I gotta go look at the charts. We're waiting for news to create rallies, of course, but while we wait... the price action Game, plays these games.
👍️ 1
Pazzo1212 Pazzo1212 4 시간 전
As soon as the MAA is officially accepted by the EMA, does Missling and team put on a full court press on to find a global partner?  We don't have an experienced sales team with existing market penetration, so we need a team trained and ready to hit every European country full bore.  

Thoughts? 


👍️ 1
123tom 123tom 4 시간 전
I'm bullish long term, Steve, but watching how AVXL is trading these days, It just looks like price is getting tossed up and down like a rag doll. I've watched this trading game for 13 years with avxl, ... It was an automatic sell target around 10 ,in my view. Pullback targets to buy now...🎱🤔🫣... for me, something below 8... maybe 7.50 area.... and see if that pivot support shoulder holds there. But decisions should be flexible as the picture changes and dictates. Right now, my swing trade targets are looking at that 7.50 area to buy and I'll take the double at 15. Not giving advice for anyone, just my current thinking here. It took a whole year of patient waiting to be able to recover last year's false rally, when we were all hyped up thinking 2024 would be a jackpot year.... I bought on the way up, shares around 9 and 10, I got stuck holding until now. Portfolio looks good now.
7.50/7.25/7.00/6.80/6.50... where are the key moving averages now on the charts ?
👍️ 1
B60611 B60611 4 시간 전
FUDrrrrol accusing someone else of misleading. Effing rich. I generally don’t see any of your posts for obvious reasons but apparently blocking someone doesn’t stop them from seeing mine.

I described it exactly as it happened, as I followed it closely at the time.
👍️0
sab63090 sab63090 4 시간 전
Hoskuld
Well, you know that I think you are the same type as I believe I am....trying to be honest with others! You have expertise that I don't have so I do rely on you and others to keep me informed on the science and your experience in the industry. I appreciate it!
👍️ 2 💯 1
baltimorebullet baltimorebullet 4 시간 전
That's also how I see it.
👍️ 1
Hoskuld Hoskuld 5 시간 전
Will we see OLE data in the paper though...
👍️ 2
Hoskuld Hoskuld 5 시간 전
Hi Sab. I am not a TA guy but this is going higher. When, I don't know. But is the MAA is accepted (and the rapporteur process almost guarantees it) then Anavex should see another 20 points added leading into the decision. And the 3-71 biomarkers like up with Karuna's biomarkers (maybe a little better?) so we may get another step-wise increase in valuation next Summer.
👍️ 4
Hosai Hosai 5 시간 전
It would be surprising if results in the peer review deviated much from those presented by Dr Sabbagh on Oct 31st (which showed a 0.008 p value in ADAS COG ITT dosed vs placebo and a 50% decrease in SIGMA WT ADAS COG dosed vs placebo) considering there has only been 3-4 weeks since then and the back and forth and considerations with the journal would be slow.
👍️ 1
bas2020 bas2020 5 시간 전
Yep... I sold it, too, Tom. The collusive manipulators were not going to let it get above the $10.38 200MA resistance. The 2yr (weekly) chart looks like they could take it back to the mid $6s, while waiting for the next bit of news which will be weeks away. Will be patiently waiting.
👍️ 2 😂 1
Investor2014 Investor2014 5 시간 전
I would give it to the other side of the holidays for the $AVXL price to settle in a some level, but not expecting a major price increase on the MAA submission news. Just hopefully some solid stability until more news of progress is available on the MAA filing and other outstanding catalysts beginning to happen next year.
👍️ 2
sab63090 sab63090 5 시간 전
Normally after a reversal like we had today the stock CRASHES right into the close and prints on the low....instead it seems we have partially stabilized...won't know for sure until tomorrow though...maybe I'm just mad at being wrong on what I thought was going to be a sharp push higher...😡.
👍️ 1
Steady_T Steady_T 5 시간 전
I think that tomorrow we will see if the filing has any real impact on the SP.

What the paper has to say is going to be important. If it strongly supportive of the trial results it could have an significant impact. If it is more nuanced, it might not have much impact at all. We will just have to wait and see what it has to say.

If you look up Anavex in the dictionary it is defined as a synonym for waiting.
👍️ 4
sab63090 sab63090 5 시간 전
Steady T
I totally agree with that conclusion....I was wrong in thinking that the move would continue up, but close at least seemed to have stopped the pain; maybe tomorrow we bounce a little and above $9.50 would improve my outlook quite a bit.
👍️ 1
sab63090 sab63090 5 시간 전
Good call, Tom! I see you are remaining/leaning to a bearish outcome & even though I did NOT get this right, I'm still thinking the the momentum is not entirely lost, so I remain bullish and will wait this out....back to my closet...cheers!
👍️ 2
plexrec plexrec 5 시간 전
" fomo up 58 cents!"---on 1 share !!!!! What a joke !!!!
👍️0
sab63090 sab63090 5 시간 전
Kentucky:

Yes that's a plus; and after seeing the close today and being slapped on my earlier bullish impressions, the close wasn't too bad either.
👍️0
Steady_T Steady_T 5 시간 전
My guess on today's trading is the MMs sold short on the pop up and first hour, then works the SP down as they covered their opening hour shorts.
👍️ 4

최근 히스토리

NASDAQ
AVXL
Anavex Life Sciences
EU
AGGH
Global Aggregate Bond UC...
NYSE
LAC
Lithium Americas
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유